In a patient with major depressive disorder and anxiety who started sertraline (Zoloft) 25 mg one week ago and now has new‑onset jaw clenching (bruxism), how should this adverse effect be managed?

Management of Sertraline-Induced Jaw Clenching (Bruxism)

Immediately add buspirone 5 mg daily at bedtime to treat the sertraline-induced bruxism while continuing the sertraline for depression and anxiety. This approach allows you to maintain therapeutic benefit from the SSRI while effectively managing the movement disorder side effect.

Understanding SSRI-Induced Bruxism

Bruxism (jaw clenching and teeth grinding) is a recognized adverse effect of SSRIs, including sertraline, occurring in the first few weeks of treatment 1. The FDA label for Zoloft explicitly lists bruxism as a known adverse effect that typically emerges within the first few weeks of treatment 2. This patient's presentation at one week is consistent with the typical onset window of 3-4 weeks reported in systematic reviews 3.

The mechanism likely involves serotonergic-mediated inhibition of dopamine pathways, creating an imbalance that manifests as movement disorders 4, 3.

Primary Management Strategy: Buspirone Augmentation

The evidence strongly supports adding buspirone 5 mg daily (typically at bedtime) as first-line management 3, 5, 6. This approach has several advantages:

• Rapid resolution: Symptoms typically improve within 3-4 days to 4 weeks of buspirone initiation 4, 5
• Preserves antidepressant efficacy: Allows continuation of sertraline for the underlying depression and anxiety
• Well-documented success: Multiple case reports and case series demonstrate consistent effectiveness 3, 7, 5, 6
• Mechanism: Buspirone's 5-HT1A partial agonist activity may counterbalance the serotonergic-dopaminergic imbalance

The buspirone dose can be titrated up to 10-15 mg daily if 5 mg is insufficient, though most patients respond to low doses 4, 5.

Alternative Management Options

If buspirone is unavailable or ineffective, consider these alternatives in order:

Option 2: Dose Reduction

• Reduce sertraline to 12.5 mg daily (half the current dose)
• Monitor for both bruxism improvement AND maintenance of psychiatric benefit
• Caveat: This may compromise treatment of the underlying depression/anxiety, which is suboptimal given the patient just started treatment 1

Option 3: Switch to Alternative Antidepressant

• Consider switching to an antidepressant with lower bruxism risk
• Escitalopram or citalopram may have fewer CYP450-related interactions and potentially lower movement disorder risk 1
• Important: Requires tapering sertraline and cross-titration, delaying therapeutic benefit for the psychiatric condition

Option 4: Low-Dose Quetiapine

• Quetiapine 25-50 mg at bedtime has shown efficacy through 5-HT2 receptor antagonism 7
• Consider if buspirone fails or is contraindicated
• Monitor for metabolic side effects with longer-term use

Monitoring and Follow-Up

Close monitoring is essential during the first 1-2 weeks 8:

• Assess bruxism severity (jaw pain, tooth damage, sleep disruption)
• Monitor for worsening depression or anxiety symptoms
• Screen for other SSRI adverse effects (behavioral activation, suicidal ideation per FDA boxed warning) 2
• Consider dental referral if tooth damage is suspected 4, 3

The AACAP guidelines emphasize that adverse effects like bruxism typically emerge within the first few weeks and support slow up-titration with close monitoring 1.

Critical Pitfalls to Avoid

1. Do not simply discontinue sertraline abruptly: This risks both discontinuation syndrome and untreated psychiatric illness 1, 2

2. Do not ignore the symptom: Bruxism can cause significant tooth damage, TMJ problems, and sleep disruption if left untreated 4, 3

3. Do not assume it will resolve spontaneously: While some SSRI side effects diminish over time, bruxism typically persists without intervention 3, 6

4. Do not delay treatment: The patient is only one week into therapy for MDD and anxiety—maintaining adherence is critical for long-term psychiatric outcomes 8

Pharmacogenetic Considerations

If bruxism persists despite buspirone augmentation, pharmacogenetic testing for CYP2C19 and CYP2D6 may guide alternative antidepressant selection 4. Patients with CYP2C19 reduced-function alleles (*2/*17) may be at higher risk for sertraline-related movement disorders and may benefit from switching to venlafaxine or other non-SSRI alternatives with pharmacogenetic guidance.

Patient Education

Inform the patient that 2:

• Bruxism is a known side effect of sertraline that can be effectively managed
• Adding buspirone should resolve symptoms within days to weeks
• They should continue sertraline for their depression and anxiety
• They should report any worsening jaw pain, tooth damage, or new psychiatric symptoms immediately
• This side effect does not mean they cannot take antidepressants—it just requires adjustment